Immunology Clinical Trials Update: Week 44, 2026

Published October 30, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

This Phase 3 follow-up study looks at how well DBV712, an oral treatment for peanut allergy, works over the long term in young children. The trial involved over 300 children in the United States and showed results that may help reduce allergic reactions and improve day-to-day life for kids with peanut allergies. This treatment could become an important option for families managing this common and sometimes severe allergy.

Understanding Poor Vaccine Responses to Hepatitis B Vaccination

This Phase 4 study is exploring why some people do not respond well to the standard hepatitis B vaccine. It is testing two different hepatitis B vaccines in about 101 participants who have shown poor immune responses. The goal is to find which vaccine offers better protection, which could help improve vaccination strategies for those who currently remain at risk despite vaccination.

Erythropoietin Therapy to Induce Regulatory T Cells in Liver Transplant Recipients

This Phase 4 trial tested erythropoietin therapy in liver transplant patients to increase regulatory T cells, which help the body accept the new liver and reduce rejection risks. Nine stable transplant recipients participated, and the study has finished with results available. If successful, this approach may reduce the need for stronger immune-suppressing drugs and improve transplant outcomes.

Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063

This ongoing Phase 3 trial is testing a new injection treatment called EP-088_MM09 for people with allergic rhinitis and related conditions caused by house dust mites. It is recruiting 250 participants aged 12 to 65 in Portugal and Spain. If effective, this immunotherapy could lower allergy symptoms and reduce the need for other allergy medications, offering relief to many who suffer from these common allergies.

Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063

This Phase 3 study is also testing mannan-conjugated allergoid immunotherapy for allergic rhinitis and asthma triggered by house dust mites. Recruiting in Portugal and Spain, it focuses on people with moderate to severe symptoms and controlled asthma. Positive results could provide a new way to manage these respiratory allergies, potentially reducing symptoms and reliance on daily allergy drugs.

This week’s research highlights show ongoing progress in allergy treatments, vaccine responses, and transplant care, offering hope for improved management and quality of life for patients. TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.